Alnylam Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 29, 2026, 8:16 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedAlnylam Q3 2026 Non-GAAP Diluted EPS of $16.26 Tops $2.25 Consensus on $1.9 Billion Tax Benefit; Revenue of $1.46 Billion Beats $1.43 Billion Estimate
8-KJuly 30, 2026, 8:06 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits